Difluorolactam compositions for ep4-mediated osteo related diseases and condtions
MX2018009696A
Anti-citrullinated hla polypeptide antibodies and uses thereof.
CA2930574A1
Amine salts of a prostacyclin analog
CN105392505A
Methods, systems, and compositions for promoting bone growth
AU2014229065A1
Methods of synthesizing a difluorolactam analog
WO2014144610A1
Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
KR20150130326A
Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
MX2015006972A
Methods of synthesizing a prostacyclin analog.
AU2013213705A1
Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
EP2874620A1
Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
AU2013207456A1
Skin lightening compositions
JP2012246301A
Method for preparing prostaglandins f
WO2012159072A2
Fluorescent molecular probes for use in assays that measure test compound competitive binding with sam-utilizing proteins
WO2011159741A2
Tetranor-pgem/pgam specific immunogens, antibodies, tracers, assay kits and methods for making same
CA2802387A1
Methods for manufacturing tetranor-prostaglandin d and j metabolites
WO2011159735A2
Tetranor-pgdm/pgjm specific immunogens, antibodies, tracers, assay kits and methods for making same
NZ599316A
Process for the preparation of f-series prostaglandins
AU2001233286B2
Internal 1,15-lactones of fluprostenol and related prostaglandin F2alpha analogs and their use in the treatment of glaucoma and intraocular hypertension
